viewGilead Sciences, Inc.

Coronavirus: What’s happening in the labs of pharma companies worldwide

A list of the major pharma players looking for solutions to tackle the pandemic

Coronavirus: what’s happening in the labs of pharma companies worldwide

While most of the global population is under lockdown to prevent the spread of the coronavirus, many laboratories in the pharma industry are striving to tackle the pandemic.

Some companies are repurposing or developing treatment, others are focusing on vaccines, tests or technology to deliver drugs in the body.

Existing drugs being repurposed

  • Gilead Sciences Inc’s (NASDAQ:GILD) antiviral medication remdesivir received temporary approval by the US authorities for Covid-19 treatment. The firm also agreed with five generics producers to supply it in 127 countries. Three trials confirmed that remdesivir allows for a faster recovery in patients with severe symptoms, while other studies are ongoing to confirm its safety and efficacy.
  • AstraZeneca PLC (LON:AZN) is assessing the efficacy of Calquence, normally used for blood cancer.
  • Sanofi is focusing on Plaquenil/Hydroxychloroquine, used for malaria, and rheumatoid arthritis treatment Kevzara in conjunction with Regeneron.
  • Another repurposed arthritis treatment is Swiss giant Roche’s Actemra, with clinical results expected between June and July
  • Fellow Swiss conglomerate Novartis is evaluating canakinumab, a fully-human antibody, and ruxolitinib, a treatment for bone marrow disorders.
  • Ergomed PLC (LON:ERGO) is running trials for two antibodies, namilumab (IZN-101) and siltuximab. Interim data on the latter showed that 33% of patients saw clinical improvement, with a reduced need for oxygen support, while 43% stabilised.
  • Respiratory drug developer Synairgen PLC (LON:SNG) is testing its candidate SNG001, a formulation based on interferon beta, a naturally occurring protein which orchestrates the body's antiviral responses.
  • CytoDyn Inc begun the first human trials for leronlimab (PRO 140), initially designed to treat HIV, in mid-April.
  • The University of Dundee is testing brensocatib, a treatment originally designed for long-term lung conditions. The project is funded by Insmed Incorporated (NASDAQ:INSM), the developer of the drug.
  • The University of Oxford is conducting two trials: ‘PRINCIPLE’, testing the anti-malarial drug Plaquenil-Hydroxychloroquine, and 'RECOVERY', involving several drugs: Lopinavir-Ritonavir (commonly used to treat HIV), Dexamethasone (a type of steroid, which is used in a range of conditions typically to reduce inflammation), Hydroxychloroquine (related to an anti-malarial drug), Azithromycin (a commonly used antibiotic), Tocilizumab (an anti-inflammatory treatment given by injection). 


New treatment



  • The Jenner Institute at Oxford University signed a deal with AstraZeneca PLC (LON:AZN), which will produce and distribute 100mln doses. The UK government has secured 30mln jabs to receive by September.
  • Imperial College London is also studying a candidate.
  • The UK government has funded the Vaccines Manufacturing Innovation Centre, scheduled to open in summer 2021. It is supported by Johnson & Johnson (NYSE:JNJ) and Merck & Co. (NYSE:MRK) among others and will have capacity to produce enough vaccine doses to cover the UK population in six months.
  • GlaxoSmithKline PLC (LON:GSK) and French rival Sanofi have agreed to develop a candidate that is scheduled to enter clinical trials in the second half of 2020 and be ready by 2021.
  • Biotech company Moderna Inc (NASDAQ:MRNA) developed a candidate in only 63 days, potentially entering the final phase of trials in July. If ready it could be available to some professional categories by autumn 2020.
  • Johnson & Johnson has pencilled in human clinical studies by September, with the first batches potentially available for emergency use authorisation in early 2021.
  • Pfizer Inc. (NYSE:PFE) teamed up with BioNTech (NASDAQ:BNTX) to develop four candidates, with clinical trials having started in Germany and the US.
  • Frontier IP Group PLC’s (LON:FIPP) portfolio company The Vaccine Group is working on formulations for animals to prevent coronaviruses from infecting humans again.
  • German company CureVac was subject to a tug of war between the country's government and Donald Trump, who prompted outrage by attempting to buy the low-cost coronavirus vaccine developer in March.
  • Other candidates are being studied by Inovio, the Shenzhen Geno-Immune Medical Institute, CanSino Biologicals and a partnership between Soligenix and the University of Hawaii. 


Diagnostics and equipment

  • Several companies are focusing on serology tests, which target antibodies to see whether the person has had the virus. According to analysts at Credit Suisse, they are “critical” in understanding immunity and potentially lift restrictions. Abbott and Eurofins announced the launch of their tests in mid-April, while Roche's Elecsys received approval in the US and Europe, with the UK in talks to secure a contract. The Swiss giant is ramping up production “to high double-digit millions per month”.
  • Novacyt PLC (LON:NCYT) has been one of the pioneers in swab testing, launching the first kit in February, followed by a second one, designed to deliver faster results, in March. It is manufacturing 4mln tests per month. It is also developing a new test that does not require certain extraction reagents which are lacking throughout the market.
  • Genedrive PLC (LON:GDR) is developing a test, set to be approved in May, to deliver results quickly in close proximity to patients, rather than needing to send samples to labs to be tested and waiting for a conclusive result.
  • Inspiration Healthcare Group PLC (LON:IHC) has boosted production of ventilator machines and other crucial medical equipment for the UK.
  • Catenae Innovation PLC (LON:CTEA) has built an operational prototype of a phone app that can store and share coronavirus test information. Trialling started on 18 May.
  • Open Orphan PLC 's (LON:ORPH) subsidiary hVIVO is in an antibody testing partnership with NASDAQ-listed medical devices firm Quotient. hVIVO will use Quotient’s recently-certified MosaiQ system to screen for SARS-CoV-2 antibodies, with operations set to start in the first days of June.
  • e-Therapeutics PLC (LON:ETX) has re-purposed an existing platform to test approved and known drugs, both alone and as combinations, for Covid-19 treatment. 

Quick facts: Gilead Sciences, Inc.

Price: 73.34 USD

Market: NASDAQ
Market Cap: $92 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Covid Technologies looking for large growth after being...

Micron Waste Technologies (CSE: MWM- OTC: MICWF) soon to be subsidiary COVID Technologies President Harvey Sidhu joined Steve Darling from Proactive Vancouver to discuss his company being acquired by Micron. Sidhu discusses his company which makes PPE or personal protective equipment....

7 hours, 47 minutes ago

6 min read